Search - tctmd.com

Displaying 1 - 4 of 4

Sort: Relevancy | Date

Clear CVD Risk Reduction With PCSK9 Inhibitors, but No Mortality Effect: Meta-analysis

News Conference News EAS 2019

Clear CVD Risk Reduction With PCSK9 Inhibitors, but No Mortality Effect: Meta-analysis

Michael O'Riordan

May 28, 2019

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

News Daily News

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

Michael O'Riordan

April 29, 2019

Alirocumab Price Cut Makes Second PCSK9 Inhibitor More Affordable

News Daily News

Alirocumab Price Cut Makes Second PCSK9 Inhibitor More Affordable

February 12, 2019

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

News Features

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

Michael O'Riordan

February 01, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.